Clinical Trials Logo
  1. Home
  2. HIV-1 Infection
  3. NCT04061889
  4. Details
NCT04061889 Clinical Trial

Clinical Epidemiology Cohort Study for Patient Living With HIV

HIV-1 Infection Clinical Trial

Official title:
Clinical Epidemiology Cohort Study for Patient Living With HIV

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04061889
Other study ID # VGHKS19-CT4-02
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2019
Est. completion date March 31, 2022

Study information
Verified date August 2019
Source Kaohsiung Veterans General Hospital.
Contact Hung Chin Tsai, MD, PhD
Phone +886-7-3468299
Email Hctsai1011@yahoo.com.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a retrospective observational cohort study for the patient living with HIV aiming to understand more in disease progress, resistant mutation, comorbidity, and common coinfection.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patient living with HIV receiving follow-up in Kaohsiung VGH

Exclusion Criteria:

- not applicable

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• intervention name is not applicable
Another intervention is not applicable either, due to the observational study design

Locations
Country Name City State
Taiwan Kaohsiung Veteran General Hospital Kaohsiung Kaohsiung City

Sponsors (1)
Lead Sponsor Collaborator
Kaohsiung Veterans General Hospital.

Country where clinical trial is conducted

Taiwan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Hazard ratio of cohort epidemiology characteristics in treatment failure, renal failure and hepatitis D coinfection on average of 3 year
See also
  Status Clinical Trial Phase
Completed NCT03188523 - Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) Phase 1
Active, not recruiting NCT06185452 - Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine Phase 4
Recruiting NCT02881320 - Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 Phase 2/Phase 3
Completed NCT02513771 - Sitagliptin for Reducing Inflammation and Immune Activation Phase 2
Completed NCT02542852 - A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia Phase 2
Terminated NCT02732457 - Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients
Completed NCT02057796 - Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Phase 4
Completed NCT01989910 - Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Phase 4
Completed NCT01704781 - Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) Phase 1/Phase 2
Completed NCT01627678 - Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART Phase 1/Phase 2
Completed NCT01403051 - High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART Phase 2
Completed NCT01348308 - Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Phase 3
Completed NCT01466595 - Rifaximin as a Modulator of Microbial Translocation and Immune Activation Phase 2
Completed NCT01019551 - Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients Phase 2
Completed NCT01511809 - Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression Phase 3
Terminated NCT01130376 - Novel Interventions in HIV-1 Infection Phase 1
Completed NCT00323687 - SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada Phase 4
Completed NCT04003103 - Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) Phase 2
Completed NCT02527096 - A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol) Phase 2
Active, not recruiting NCT04776252 - Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) Phase 3